Israel - hebraisk - Ministry of Health

medison pharma ltd - tipiracil as hydrochloride; trifluridine - טבליות מצופות פילם - tipiracil as hydrochloride 6.14 mg; trifluridine 15 mg - trifluridine, combinations

Israel - hebraisk - Ministry of Health

medison pharma ltd - tipiracil as hydrochloride; trifluridine - טבליות מצופות פילם - tipiracil as hydrochloride 6.14 mg; trifluridine 15 mg - trifluridine, combinations

Israel - hebraisk - Ministry of Health

medison pharma ltd - tipiracil as hydrochloride; trifluridine - טבליות מצופות פילם - tipiracil as hydrochloride 8.19 mg; trifluridine 20 mg - trifluridine, combinations

Israel - hebraisk - Ministry of Health

medison pharma ltd - tipiracil as hydrochloride; trifluridine - טבליות מצופות פילם - tipiracil as hydrochloride 8.19 mg; trifluridine 20 mg - trifluridine, combinations

Israel - hebraisk - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; ivacaftor; tezacaftor - טבליות מצופות פילם - ivacaftor 75 mg; tezacaftor 50 mg; ivacaftor 75 mg - ivacaftor and tezacaftor

Israel - hebraisk - Ministry of Health

novartis israel ltd - metoprolol tartrate - טבליות בשחרור איטי - metoprolol tartrate 200 mg - metoprolol - metoprolol - hypertension, angina pectoris, arrhythmia, prophylaxis of migrain, prophylaxis of reinfarction.

Israel - hebraisk - Ministry of Health

ferring pharmaceuticals ltd - somatropin - אבקה וממס להכנת תמיסה להזרקה - somatropin 10 mg - somatropin - somatropin - short stature due to pituitary growth hormone deficiency turner's syndrome, children suffering from renal insufficiency. children : short stature due to inadequate or failed secretion of pituitary growth hormone or turner's syndrome. short stature in children with renal insufficiency.

Israel - hebraisk - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu/ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

Israel - hebraisk - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

Israel - hebraisk - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).